source
- cAMPfield Therapeutics raises $180 million to develop oral IBD drug prifemilastcAMPfield Therapeutics, a California biotech, announced a $180 million Series A financing to advance its oral anti‑inflammatory candidate for inflammatory bowel disease. The investigational drug,…
- CMS recalculates 2026 Medicare Advantage star ratings, increasing program volatility and affecting $16 billion in bonusesFederal officials have issued a new memo that recalculates the quality ratings for 2026 Medicare Advantage plans. The change follows another lawsuit from insurers that contest lower star ratings,…